

November 19, 2021

To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 th Floor, Dalal Street Mumbai – 400001 Code: 540222	To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051 Code: LAURUSLABS
--	---

Dear Sirs,

Sub: Press Release titled – “Laurus Labs acquires substantial minority stake in a CAR-T cell therapy company - ImmunoACT”.


The Company is pleased to announce that it has signed an investment agreement with Immunoadoptive Cell Therapy Private Limited (ImmunoACT), an advanced cell and gene therapy company to acquire 26.62% stake (fully diluted basis) for a cash consideration of approximately Rs. 46.00 Crores, subject to the fulfilment of certain conditions. Additionally, senior management of Laurus Labs would also invest in ImmunoACT for a 5.64% stake for approximately Rs. 9.75 crore at same price and terms.

This investment in ImmunoACT is part of the larger strategy to strengthen biologics business of the Company and this provides access and entry into an emerging field of research.

A press release to this extent is also attached for your information and records.

Thanking you,

Yours sincerely,
For Laurus Labs Limited


G. Venkateswar Reddy
Company Secretary



Encl: As above

Laurus Labs acquires substantial minority stake in a CAR-T cell therapy company - ImmunoACT

Hyderabad, November 19, 2021, Laurus Labs Ltd. (Laurus BSE: 540222, NSE: Lauruslabs, ISIN: INE947Q01028)

Laurus Labs has signed an investment agreement with Immunoadoptive Cell Therapy Private Limited (ImmunoACT), an advanced cell and gene therapy company to acquire 26.62% stake (fully diluted basis) for a cash consideration of approximately Rs. 46.00 Crores, subject to the fulfilment of certain conditions. Additionally, senior management of Laurus Labs would also invest in ImmunoACT for a 5.64% stake for approximately Rs. 9.75 crore at same price and terms.

ImmunoACT was founded in 2018 under the aegis of IIT Bombay incubator, Society for Innovation and Entrepreneurship (SINE) by Dr. Rahul Purwar. ImmunoACT has strong global partnerships including Dr. Carl June, pioneer of CAR-T therapy as member of scientific advisory board. ImmunoACT has portfolio of CAR-T therapy assets under various development stages for the treatment of multiple auto immune diseases and oncology indications. The current promoters of ImmunoACT will continue to lead the management and operations of ImmunoACT.

Laurus labs investment in ImmunoACT is part of the larger strategy to strengthen biologics business of Laurus Labs and this provides access and entry into an emerging field of research. CAR-T therapy is very promising treatment option which has had great success in the western part of the world. In India, CAR-T therapy is not available and this collaboration will help us in bringing this novel technology to the Indian patients at a very affordable pricing.

Commenting on this development, CEO of Laurus Labs Dr. Satyanarayana Chava said, “we are very excited to partner with ImmunoACT to bring novel CAR-T therapy to patients in India and other markets at an affordable pricing. This partnership will help us in bringing innovative cell and gene therapy products to patients in India and other markets. ImmunoACT has great leadership team with proven expertise in CAR-T technology and we are confident that these products will benefit patients with better outcomes”.

Dr. Rahul Purwar, CEO of ImmunoACT said, “We are very excited about partnering with Laurus Labs Limited. The partnership between ImmunoACT and Laurus Labs will provide strategic thrust to our ambitions to establish innovative opportunities in the healthcare industry through new age Cell and Gene based therapies. It also provides synergies to both organizations to leverage each other's strengths in making India a global hub for innovation for R&D of cellular immunotherapy supported by the global distribution and reach of Laurus Labs”.

About Laurus Labs Limited :

About Laurus | Laurus Labs is a fully integrated pharmaceutical and biotechnology company, with a leadership position in generic Active Pharmaceutical Ingredients (APIs) with a major focus on Anti-Retro Viral, Hepatitis-C, Cardiovascular, Anti-Diabetic, Anti-Asthma, and Gastroenterology. Central Nervous System (CNS), Proton Pump Inhibitors (PPIs) and Oncology drugs. We also develop and manufacture oral solid formulations, provide contract research and manufacturing services (CRAMS) to Global pharma companies, and produce specialty ingredients for nutraceuticals, dietary supplements and cosmeceuticals. We do animal origin free recombinant proteins in biotechnology. **Corporate Identification No: L24239AP2005PLC047518.** For more information visit www.lauruslabs.com

About ImmunoACT and the promoter:

Immunoadoptive Cell Therapy Private Limited (ImmunoACT) is a pioneer in the field of Cell and Gene Therapy. It is in the process of becoming India's first company to introduce the CART therapy for cure of specific types of Blood Cancers which are currently in Clinical Trials.

ImmunoACT was founded in 2018 under the aegis of IIT Bombay incubation programme (Society for Innovation and Entrepreneurship) by Dr. Rahul Purwar and a team of eminent scientists. It has an experienced team from the fields of science and business, strong partnership with eminent institutions like Tata Memorial Hospital. Dr Carl June, one of the pioneer in T-Cell therapies for the treatment of Cancer, is a member of its scientific advisory board.

Dr Purwar has done his PhD in molecular medicine from Hannover Medical School, Germany and has been a Research Fellow at Harvard Medical School. He also had a stint as scientist at Immunogen Inc., MA, USA prior to dedicating his work life towards research and development of cellular and gene based therapies. His research work is published in highly prestigious journals like Nature Medicine etc. He has been awarded with several awards including Melissa K. Bambino Memorial Award by The Skin Cancer Foundation, USA. For more information visit www.immunoact.com

-ENDS-

Pavan Kumar N
Laurus Labs Ltd.
Tel: +91 40 3980 4380
Email: mediarelations@lauruslabs.com



DISCLAIMER: Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.